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Cryptococcal meningitis is the most frequent cause of meningitis and a major cause of mortality in HIV-infected adults in Africa.
This study evaluated the performance of the lateral flow assay (LFA) on cerebrospinal fluid (CSF) samples for the diagnosis of
cryptococcal meningitis against that of existing diagnostic tests. LFA performed on 465 undiluted CSF samples had a sensitivity
of 91%.When the LFA was paired with Gram staining, a sensitivity of 100%was achieved after implementation of a dilution step
for samples with negative LFA results and the presence of yeasts onmicroscopy. Microscopy is essential for preventing the re-
porting of false-negative results due to the high-dose “hook” effect.
Cryptococcal meningitis (CM) is a frequent HIV-related op-portunistic infection caused by Cryptococcus neoformans
(serotypes A and D) andCryptococcus gattii (serotypes B and C) (1,
2). It is the main cause of adult meningitis in sub-Saharan Africa
(SSA) (3–5) and is a major cause of HIV-related mortality, ac-
counting for between 13 and 44% of deaths in HIV-infected co-
horts in resource-limited countries (3). Case fatality rates remain
unacceptably high. Locally, the 30-day mortality rate is 33 to 41%
in routine settings (6, 7), possibly related to delayed diagnosis and
the commencement of appropriate combinations of antifungal
therapy (3, 8, 9). Despite the high case fatality ratio (7, 9, 10), these
patients may have good long-term survival rates, if they are able to
overcome the acute phase of the illness (8). Key factors influencing
survival are the fungal burden at presentation and the rate of ster-
ilization of cerebrospinal fluid (CSF) with combination treatment
(6, 8, 9, 11, 12). The rapid and accurate laboratory diagnosis of CM
is thus important to enable the timely use of appropriate medication
and prevent diagnostic delays contributing to increased CSF fungal
loads and poor clinical outcomes (6, 11, 13, 14).
The rapid detection of Cryptococcus has previously been ham-
pered by the lack of a point-of-care (POC) test for CM. The stan-
dard diagnostic methods include India ink staining, the conven-
tional cryptococcal latex agglutination test (CLAT), and culture of
CSF which is generally performed by trained technical staff, pre-
dominately at centralized laboratories. Samples are referred from
peripheral hospitals and clinics in South Africa (SA) with subse-
quent delays in the return of results to the sites of patient manage-
ment. The CLAT is labor intensive, and sample batching may fur-
ther delay the turnaround time. Cultures may be negative or slow
to grow for patients with low fungal burdens or those already
receiving treatment. Prolonged fungal culture often results in bac-
terial contamination and further delays as the isolate is purified.
Given the high mortality rate of CM, it is clear that initiation of
treatment cannot be delayed pending culture results (15).
The recent development of the cryptococcal antigen lateral
flow assay (LFA) (IMMY, Norman, OK, USA), a commercially
available rapid diagnostic test that detects capsular polysaccharide
antigens of the four major cryptococcal serotypes (A and D for C.
neoformans and B and C for C. gattii), has addressed some of the
limitations of the current diagnostic tests (1). The LFA is essen-
tially a sandwich immunochromatographic assay adapted to op-
erate along a single axis to suit the dipstick (test strip) format. The
test uses specimen wicking to capture gold-conjugated, anti-cryp-
tococcal antigen (anti-CrAg) monoclonal antibodies and gold-
conjugated control antibodies on the test membrane.
The LFA has proved to be inexpensive, stable at room temper-
ature, and easy to perform. Early demonstration studies have
shown that the LFA has a high level of agreement with conven-
tional antigen tests when performed on urine and serum samples
(16). The LFA has been FDA approved for use on CSF samples, but
published data on the sensitivity and specificity compared to those
of the CLAT and culture are limited (1, 17). The aim of this study
was to evaluate the performance of the LFA on CSF samples for the
diagnosis of CM compared to that of the CLAT and culture, which
together with microscopy are the current diagnostic tests em-
ployed at the National Health Laboratory Services (NHLS) labo-
ratories in SA.
MATERIALS AND METHODS
Clinical samples. Consecutive CSF samples from patients with suspected
CM referred to the NHLS microbiology laboratory at Tygerberg Hospital,
Cape Town, SA, were prospectively collected during October 2012. Pa-
tients included those with clinically suspected or confirmed HIV infection
with signs and/or symptoms suggestive of meningitis. Samples were in-
cluded in the study if there was a sufficient amount for analysis after
routine laboratory investigations had been performed. The study was ap-
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proved by the Health Research Ethics Committee of the Faculty of Health
Sciences at Stellenbosch University.
Laboratory investigations. The LFA was performed on CSF samples
according to the manufacturer’s instructions: 40l of sample diluent was
mixed with 40l of CSF in a disposable tube, followed by insertion of the
LFA test strip. Results were read after 10 min (18). A positive result was
reported if two visible lines developed over the control and test areas, and
a negative result was reported if a single control line was present (18). If
the LFA was negative but Gram staining demonstrated the presence of
yeasts, the LFA was repeated with a dilution of the CSF: 40 l of sample
diluent was mixed with 40 l of CSF plus 40 l of titration diluent (1:2
dilution). The LFA test strip was then inserted and read as above. Test
strips from 10 different allotments were used during this study.
Gram stains and bacterial and fungal cultures were performed on CSF
samples according to the laboratory protocols. CSF samples were referred
for additional investigations according to clinicians’ requests (e.g., tuber-
culosis [TB] or VDRL test). Selective agar (Sabouraud dextrose) for yeast
isolation was utilized and incubated aerobically at 35°C for 14 days to
ensure optimal growth (15). Cryptococcus species were identified on the
automated Vitek 2 platform (bioMérieux, France) (19) or AuxaColor 2
(Bio-Rad, Marnes-la-Coquette, France) colorimetric sugar assimilation
test. The cryptococcus antigen latex test (CLAT) (Remel, Inc., Lenexa, KS,
USA) for detecting capsular polysaccharide (CPS) antigens of C. neofor-
mans, using murine IgM monoclonal antibodies, was performed accord-
ing to the manufacturer’s instructions (20). Pronase and heat-inactivation
treatments were not performed on the CSF samples prior to performance
of the CLAT. Laboratory testing was conducted in an ISO-accredited fa-
cility. The investigators who performed the LFA testing were blinded to
the CLAT and culture results.
Data analysis. The performance of the LFA was assessed by determin-
ing the sensitivity and specificity of the test in comparison to those of the
CLAT. Results were reanalyzed using culture as a reference standard.
Agreements between the diagnostic tests were summarized using kappa
statistics and analyzed using McNemar’s test of equality of paired propor-
tions.
RESULTS
A total of 465 CSF samples were included in the study over a
period of 1 month. The samples included CSF obtained from adult
and pediatric patients.
Analysis using the CLAT as a reference standard. The lateral
flow assay performed on 465 undiluted CSF samples detected
cryptococcal antigen in 31 samples (6.7%). In contrast, cryptococ-
cal antigen was detected by the CLAT in 33 (7.1%) samples. Three
(0.6%) samples were CLAT positive but LFA negative. All three
samples showed numerous yeast cells on Gram staining and were
LFA positive after a further 1:2 sample dilution. When a positive
CLAT result was used as a gold standard, the sensitivity and spec-
ificity for the LFA on undiluted CSF samples were 90.9% and
99.8%, respectively (Table 1). After sample dilution, the sensitivity
improved to 100% (Table 2). Clinical data from these 3 patients
were retrieved and are summarized in Table 3. Of the 31 LFA-
positive samples, 30 CSF samples were CLAT positive; thus, one
additional case, for which the culture yielded no growth, was de-
tected using the LFA. This sample was from a patient known to
have had prior CM and who most likely had low-level antigenemia
undetectable by the CLAT and a negative culture due to prior
antifungal therapy. Assuming, therefore, that this positive LFA is a
true-positive result yields an LFA specificity of 100%.
Analysis using CSF culture as the reference standard.C. neo-
formans was cultured on selective medium in 26 (5.6%) CSF sam-
ples sent for analysis. All culture-positive samples were CLAT pos-
itive, and 23 were LFA positive. The three discordant samples were
those described above, which after sample dilution were also pos-
itive using the LFA. Of the 439 patients with a negative culture
result, 7 (1.6%) were CLAT positive and 8 (1.8%) were LFA pos-
itive.
DISCUSSION
Our study found that the LFA had a sensitivity of 100% for the
diagnosis of CM when samples suspected of having a high organ-
ism load were diluted before the assay was performed. However,
when performed on undiluted CSF samples, the LFA had a sensi-
tivity of only 90.9% compared to that of the CLAT as the reference
standard. This reduced sensitivity could possibly be due to the
high-dose “hook” effect (18, 21) (also referred to as prozoning),
one of the potential limitations of the LFA described by the man-
TABLE 1 Results of the lateral flow assay and conventional cryptococcal
latex agglutination test performed on 465 CSF samples before and after
CSF dilution
LFAa result
CLATb result (no. of indicated result)
Positive Negative Total
Predilution
Positive 30 1c 31
Negative 3 431 434
Total 33 432 465
Postdilutiond
Positive 33 1c 34
Negative 0 431 431
Total 33 432 465
a LFA, lateral flow assay.
b CLAT, cryptococcal latex agglutination test.
c This sample was from a patient known to have had prior CM and who most likely had
low-level antigenemia undetectable by the CLAT with a negative culture due to prior
antifungal therapy.
d All samples were analyzed using the LFA according to the manufacturer’s instructions:
1 drop of sample reagent was added to 40 l of CSF. A further 1 in 2 dilution step was
performed for samples which were LFA negative but contained yeast cells on
microscopy.
TABLE 2 Performance of the lateral flow assay and conventional
















CLATd 465 91 99.8e 96.8 92.9 0.9329
Culture 465 88.4 98.1 74.1 99.3 0.7945
LFA postdilutionf
CLAT 465 100 99.8e 97 100 0.9839
Culture 465 100 98.1 76.4 100 0.8576
a LFA, lateral flow assay.
b PPV, positive predictive value.
c NPV, negative predictive value.
d CLAT, cryptococcal latex agglutination test.
e The specificity of the LFA test was 100% when a single sample from a patient known
to have had prior CM and who most likely had low-level antigenemia undetectable by
the CLAT and culture due to prior antifungal therapy was assumed to be a true-positive
result.
f All samples were analyzed using the LFA according to the manufacturer’s instructions:
1 drop of sample reagent was added to 40 l of CSF. A further 1 in 2 dilution step was
performed for samples which were LFA negative but contained yeast cells on
microscopy.
Validation of the Cryptococcal LFA on CSF Samples
December 2014 Volume 52 Number 12 jcm.asm.org 4173
ufacturer (18). This occurs when excess analyte, in this case high
concentrations of the cryptococcal antigen, resulted in decreased
visual intensity of the test lines or, as also in this case, yielded
negative test results (18). Exceedingly high concentrations of un-
bound CrAg may out-compete the gold-labeled antibody-antigen
complex that normally wicks up the membrane to interact with
the test line which has the immobilized anti-CrAg monoclonal
antibodies. The latter reaction will result in a visible test line, but
unbound CrAg interacting avidly with the monoclonal antibodies
will result in no line. This effect may be negated by changing the
dilution of the assay.
The 3 false-negative LFA results showed numerous yeast cells
on microscopic examination of the CSF Gram stain, and the cul-
ture grew the organism after a mean incubation period of 48 h.
These false negatives were corrected after a 1:2 dilution, allowing
the sensitivity of the diagnostic LFA to reach 100%.
This is the first report of a probable high-dose hook effect with
cryptococcal LFA testing of CSF and is a limitation that clinicians
and diagnostic laboratory staff need to be aware of. A negative LFA
test, with a Gram or India ink stain demonstrating yeast cells,
should prompt LFA retesting using serial dilutions of the CSF
sample. Use of the LFA for antigen detection in CSF samples in
conjunction with staining and microscopy should, therefore, di-
agnose all cases of CM with a sensitivity that is equivalent or su-
perior to the CLAT.
The calculated specificity of the LFA in this study should be
interpreted with caution, as the CLAT is not an ideal reference
test. The LFA has been reported to detect lower levels of antigen
than the conventional latex agglutination tests (1, 22). Further-
more, the LFA is known to detect antigens of C. gattii infection (1,
20) with a higher sensitivity than the current latex agglutination
tests (23). In our study, the species was not identified in the single
discordant case (with the positive LFA but negative CLAT result)
due to the negative culture.
Despite the possibility of the high-dose hook effect observed
with the LFA in a small number of CSF samples with visible cryp-
tococci on Gram stains, the LFA remains an attractive test for use
in most settings. The LFA is stable at room temperature, has a
rapid turnaround time with results available within 10 min, and
does not require sample pretreatment or processing except in cases
suspected of having a high organism load, where serial dilution is
required. Minimal equipment is necessary to perform this rela-
tively inexpensive test, and in settings where laboratory staff are
often overworked, the major advantage of the LFA over the cur-
rent latex agglutination or previous enzyme immunoassays is its
ease of use. A further potential advantage of the LFA is its utility as
a POC test, but there are limited data on the POC use with CSF
samples (24). Potential difficulties in achieving widespread imple-
mentation of the LFA as a POC diagnostic test for CM include the
need for supplementary microscopy results with CSF samples and
the need to ensure proper quality control of the assay in the hos-
pital setting. Much progress has been made in introducing similar
assays for the diagnosis of malaria at POC facilities. Given the scale
of the HIV pandemic and the substantial morbidity and mortality
rates associated with CM, particularly in peripheral hospitals, a
similar approach for the diagnosis of CM should be undertaken.
In summary, the LFA is a simple, inexpensive test that allows
reliable detection of Cryptococcus neoformans antigens in CSF
samples, provided a microscopy result is available, and might re-
place the traditional diagnostic method of latex agglutination. A
negative test with a positive microscopy finding should prompt
repeat testing using serial dilution. Alternatively, a 1:2 dilution
could be routinely performed for all undiluted samples from HIV-
positive patients or patients with a high suspicion of disease that
tested negative, but further assessment in larger cohorts with an-
tigen quantification (titers) is necessary to evaluate whether a 1:2
dilution would detect all positive patients. Nonetheless, it is im-
portant for researchers, microbiologists, and clinicians to be
aware of the potential for the high-dose hook effect.
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